Sign in to view content

Impact of Intravitreal Anti-VEGF Therapy for Severe Non-Proliferative Diabetic Retinopathy (NPDR): Analyses Through a Monte-Carlo Simulation Model

Andrew A. Moshfeghi, MD, MBA, FASRS

Video
Published 2021

Related

Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of >4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S
Allen Chiang, MD, FASRS
Updates from the Field
2019
Clinical Feasibility of Ultra-rapid, Non-pharmacologic Anesthesia for Intravitreal Injection in Patients Receiving Anti-VEGF Treatment
Cagri G Besirli, MD, PhD, FASRS
Annual Meeting Talks
2018
Efficacy and Durability of Brolucizumab in Patients Being Transitioned From Prior Anti-VEGF Therapy
Scott D Walter, MD, MSc, FASRS
Annual Meeting Talks
2021

Category: Diabetic Retinopathy

See more